CTNM Stock Summary and Trading Ideas (Contineum Therapeutics | NASDAQ:CTNM)

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics trades on the NASDAQ stock market under the symbol CTNM.

As of February 24, 2026, CTNM stock price climbed to $15.93 with 118,055 million shares trading.

CTNM has a beta of -0.25, meaning it tends to be less sensitive to market movements. CTNM has a correlation of 0.00 to the broad based SPY ETF.

CTNM has a market cap of $581.91 million. This is considered a Small Cap stock.

Last quarter Contineum Therapeutics reported $0 in Revenue and -$.45 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.06.

The top ETF exchange traded funds that CTNM belongs to (by Net Assets): VTI, VXF, IBB, SCHA, IWC.

CTNM has outperformed the market in the last year with a price return of +109.9% while the SPY ETF gained +15.8%. CTNM has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +45.5% and +4.3%, respectively, while the SPY returned +4.6% and -1.0%, respectively.

CTNM support price is $14.89 and resistance is $16.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTNM shares will trade within this expected range on the day.